Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $11.4 million.

  • Rocket Pharmaceuticals' Accumulated Expenses rose 1078.91% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 1078.91%. This contributed to the annual value of $11.9 million for FY2024, which is 2028.2% up from last year.
  • According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Accumulated Expenses is $11.4 million, which was up 1078.91% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Accumulated Expenses ranged from a high of $11.9 million in Q4 2024 and a low of $1.6 million during Q1 2022
  • Over the past 5 years, Rocket Pharmaceuticals' median Accumulated Expenses value was $6.2 million (recorded in 2021), while the average stood at $6.6 million.
  • In the last 5 years, Rocket Pharmaceuticals' Accumulated Expenses crashed by 7357.36% in 2022 and then surged by 15681.96% in 2023.
  • Quarter analysis of 5 years shows Rocket Pharmaceuticals' Accumulated Expenses stood at $4.5 million in 2021, then soared by 120.74% to $10.0 million in 2022, then dropped by 0.76% to $9.9 million in 2023, then grew by 20.28% to $11.9 million in 2024, then decreased by 4.31% to $11.4 million in 2025.
  • Its Accumulated Expenses stands at $11.4 million for Q3 2025, versus $8.0 million for Q2 2025 and $7.1 million for Q1 2025.